TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00836277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 9mg/kg IV Day 1 Cycle = 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125mg/m2 IV Day 1 and Day 8
Study: NCT02787330

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
Study: NCT01000727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Description: Lp-PLA2 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Guideline mandated therapy for individual's condition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Therapy
Description: Guideline mandated therapy for individual's condition
Study: NCT01883934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced clinic-based support/counseling
Description: Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT03703557

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sorbstar®
Description: Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Odour sampling
Description: Analyzed by the dogs of Curie Institute at the training centers
Study: NCT02896309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Study: NCT03199833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETRAINER-S2
Description: It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy
Study: NCT02175186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALBIS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03931187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive progressive muscular relaxation therapy
Description: This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 28-30 days during IVF-ET.
Study: NCT02266615

Intervention type: GENETIC
Intervention: Biobanking of biomaterial for future genetic research.
Study: NCT00169117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Songs/posters aimed at behaviour change
Description: This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
Study: NCT04350736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0903
Description: Study drug to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0903
Description: Study drug to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to be administered by inhalation
Study: NCT01479959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eole 3 ventilator - Resmed
Description: positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eole 3 ventilator - Resmed
Description: positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eole 3 ventilator - Resmed
Description: positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
Study: NCT04703127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil and Combined Dapoxietine
Description: Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxietine and Combined Lidocaine 5% Spray
Description: Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
Study: NCT01336166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: 120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 30 μg
Description: 120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 45 μg
Description: 120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 120 adults were assigned to receive 1 dose of placebo.
Study: NCT03390712

Intervention type: DRUG
Intervention: Paliperidone Palmitate
Description: Monthly injections

Intervention type: DRUG
Intervention: Risperidal Consta
Description: Bi-weekly injection

Intervention type: DRUG
Intervention: Antipsychotic
Description: Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.

Intervention type: DRUG
Intervention: Antipsychotic
Description: Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
Study: NCT01420549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
Description: Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
Description: Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
Study: NCT02072772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free group treatment
Description: See Arm Description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: See Arm Description
Study: NCT03672630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
Study: NCT00111579

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAIV-T
Description: A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.

Intervention type: OTHER
Group type: OTHER
Intervention: TIV
Description: A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
Study: NCT03082989

Intervention type: DEVICE
Intervention: fractional flow reserve performed
Description: assessing fractional flow reserve to drive revascularization

Intervention type: OTHER
Intervention: fractional flow reserve not performed
Description: description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
Study: NCT02270684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StepRite
Description: The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
Study: NCT00966810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect \> 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
Study: NCT01954069

Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative pregnancy test
Study: NCT01369849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT00502632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase and Dornase alfa
Description: Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Urokinase
Description: Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days
Study: NCT03499821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDOF ICL
Description: The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
Study: NCT02001675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging (MRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 31-phosphorous magnetic resonance spectroscopy (MRS-P31)
Study: NCT03216278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR 5/500mg
Description: Tablets for oral administration, once daily, once per treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/metformin XR 5/500 mg
Description: Tablets for oral administration, once daily, once per treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR 5/500mg
Description: Tablets for oral administration, once daily, once per treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/metformin XR 5/500mg
Description: Tablets for oral administration, once daily, once per treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR 10/1000mg
Description: Tablets for oral administration, once daily, once per treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/metformin XR 10/1000mg
Description: Tablets for oral administration, once daily, once per treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR 10/1000mg
Description: Tablets for oral administration, once daily, once per treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/metformin XR 10/1000mg
Description: Tablets for oral administration, once daily, once per treatment period
Study: NCT04039191

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS education
Description: Patients will receive additional educational SMS messages post-operatively

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SMS survey
Description: Patients will receive survey questions about post-operative pain and opioid use but no education
Study: NCT04260659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride [Dexdor]
Description: Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil [Ultiva]
Description: Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine [Ketalar]
Description: Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine [Xylocaine 2%]
Description: Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]
Description: Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl [Fentanyl WZF]
Description: Rescue dosis of 100 mcg iv will be administered if hypertension \> 140/90 mmHg or tachycardia \> 120min occurs. If necessary rescue dosis may be repeated.
Study: NCT03103906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream (Test product)
Description: Moisturizing cream with SPF (Sun protecting factor) 20

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleanser (Reference Product)
Description: Moisturizing facial cleanser

Intervention type: OTHER
Group type: OTHER
Intervention: Cleanser (Reference Product)
Description: Moisturizing facial cleanser
Study: NCT03672630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol 25 mg/kg \[MYAMBUTOL\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol 25 mg/kg \[MYAMBUTOL\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin 600 MG \[RIFADIN\]
Study: NCT02530177

Intervention type: OTHER
Intervention: Clinical Assessments
Study: NCT03103906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen (Reference Product)
Description: SPF 50 sunscreen

Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen (Reference Product)
Description: SPF 50 sunscreen
Study: NCT02545842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01023438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy for assisted uptitration
Description: Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
Study: NCT03608995

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Premaquick (Diagnostic test)
Description: PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quikcheck fFN ™
Description: - The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
Study: NCT04944407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LHP
Description: A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MM
Description: The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
Study: NCT00821184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (solifenacin)
Description: 5mg po qd

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (solifenacin) plus behavioral modification
Description: 5 mg dose po once daily plus behavioral modification
Study: NCT01850836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Study: NCT03204565

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: coronally advanced flap alone (CAF- control)
Study: NCT01806636

Intervention type: DEVICE
Intervention: PneumRx Coil System
Study: NCT04224818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual trigger
Description: Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG (standard)
Description: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
Study: NCT02530177

Intervention type: OTHER
Intervention: Clinical Assessments

Intervention type: OTHER
Intervention: Clinical Assessments